Adding value with better benefits
- Hoechst takes Roussel Uclaf. // Chemical Week;12/18/1996, Vol. 158 Issue 49, p6
Reports on Hoechst's agreement to buy the remaining shares of French pharmaceutical subsidiary Roussel Uclaf it does not own.
- Hoechst takes Roussel. // Chemical Week;2/19/1997, Vol. 159 Issue 7, p6
Reports on Hoechst's acquisition of majority shares in Roussel Uclaf.
- Hoechst buys remaining Roussel shares. // Chemical Market Reporter;12/16/96, Vol. 250 Issue 25, p5
Reports on Hoechst AG's plan to acquire all of Roussel Uclaf SA as part of a strategy to increase the value of its drug division. Value of the deal; Terms of the agreement; Benefit of the acquisition for Hoechst; Background on the operations of Roussel Uclaf.
- Hoechst, Roussel reshuffle. // Chemical Week;2/23/1994, Vol. 154 Issue 7, p8
Announces the transfer by Hoechst of Laboratories Hoechst and Albert Roussel Pharma to Roussel Uclaf (RU). Increase in stake of Hoechst at RU; Gain of access to German market by RU.
- Hoechst, Roussel changes. // Chemical Week;9/8/1993, Vol. 153 Issue 8, p6
Reports on the pharmaceutical operations of Hoechst (Frankfurt) and its subsidiary Roussel Uclaf (Paris). Changes in management; Streamlining and optimizing synergies; Antibiotics research at Roussel; Hoechst concentration on cardiovasculars.
- Company gives away RU-486 patent. // National Catholic Reporter;04/25/97, Vol. 33 Issue 25, p9
Reports on the decision of Roussel Uclaf and Hoechst AG to stop manufacturing of the drug RU-486.
- Hoechst in drugs discussions. Alperowicz, Natasha // Chemical Week;7/28/1993, Vol. 153 Issue 3, p11
Reports on Hoechst AG and its Roussel Uclaf subsidiary's negotiations to set up pharmaceutical operations in Russia and Uzbekistan. Talks for a joint venture; Akirkhin pharmaceutical complex as Russian partner; Projects for Uzbekistan.
- Roussel Uclaf reduces hours. // Chemical Week;12/11/1996, Vol. 158 Issue 48, p6
Reports on Roussel Uclaf's signing of an agreement with trade unions to reduce working hours for employees from 38 hours per week to 35. Terms of the agreement.
- U.S. drugmakers wary of RU-486. // Drug Topics;7/5/93, Vol. 137 Issue 13, p6
Reports on the delayed entry to the United States market of RU-486, an abortion pill from Roussel-Uclaf. American drug companies wary of being targets of antiabortion groups.